{"id":"8409ff67-1d2a-4e7b-997e-f341730093bf","feedVisibility":"normal","congress":119,"billType":"hr","billNumber":4963,"title":"Marijuana 1-to-3 Act of 2025","displayTitle":"2025年《大麻1类转3类法案》","abstract":"本法案将大麻从《管制物质法》的附表一调整到较低的附表。具体而言，它要求缉毒局（DEA）将大麻从附表一转入附表三。附表一管制物质是指具有高度滥用可能、目前在美国没有公认医疗用途，并受《管制物质法》规定的监管控制以及行政、民事和刑事处罚的药物、物质或化学品。附表三管制物质是指滥用可能性低于附表一或附表二物质、目前有公认医疗用途，且滥用时依赖风险为低度或中度的药物、物质或化学品。","displaySummary":"<p><strong>YVN Summary</strong></p>\n\n<p>联邦毒品法将把大麻列为滥用风险较低、有公认医疗用途的药物。法案成为法律后，司法部长有60天时间，把大麻从附表一转入附表三。附表一是最严格的类别，针对滥用风险高、且没有公认医疗用途的药物。\n\n大麻在联邦法律下仍然是受管制药物。这次调整将跳过通常的步骤，例如卫生部门的审查和公开听证会。工业大麻（hemp）仍与现在一样，不受这些毒品规定的约束。</p>","status":"COMMITTEE_CONSIDERATION","topics":["ECONOMY","ENERGY","GOVERNMENT_OPERATIONS"],"introducedAt":"2025-08-12T00:00:00+00:00","latestActionAt":"2025-08-12T00:00:00+00:00","congressGovUrl":"https://www.congress.gov/bill/119th-congress/house-bill/4963","accountabilityFlags":{"gun_laws":[],"your_money":[],"environment":[],"workers_jobs":[],"civil_liberties":[],"criminal_justice":["↓ 联邦法律对大麻的管制严格程度 — 转入附表三"],"corporate_benefits":[],"targeted_provisions":[],"high_earner_benefits":[],"transparency_accountability":["↓ 健康审查和公开听证会 — 这次调整将跳过"]},"tldr":"法案成为法律后60天内，大麻将从联邦最严格的毒品类别转入附表三。","summaryStandard":"v2","flagExplainers":{"gun_laws":[],"your_money":[],"environment":[],"workers_jobs":[],"civil_liberties":[],"criminal_justice":["司法部长将有60天时间，把大麻从最严格的附表一移出，转入附表三。大麻仍然是受管制药物。"],"corporate_benefits":[],"targeted_provisions":[],"high_earner_benefits":[],"transparency_accountability":["把药物转入新类别，通常需要先做健康和科学审查，还需要举行公开听证会。本法案直接下令调整，并把这些步骤搁置。"]},"flagValence":{"gun_laws":[],"your_money":[],"environment":[],"workers_jobs":[],"civil_liberties":[],"criminal_justice":["contested"],"corporate_benefits":[],"targeted_provisions":[],"high_earner_benefits":[],"transparency_accountability":["contested"]},"needsResummary":false,"displaySummaryHtml":null,"rawStatusText":"Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.","chamber":null,"policyArea":null,"legislativeSubjects":[],"lawStatus":null,"lawNumber":null,"latestActionText":null,"latestTextVersion":null,"textVersionUsed":null,"dateAdded":"2026-10-24T06:42:07.622918+00:00","summarizedAt":"2026-10-24T06:42:07.622918+00:00","recordId":"8409ff67-1d2a-4e7b-997e-f341730093bf","feedIdentityKey":"119/hr/4963","websiteBillId":"HR-4963","yourvoiceSummary":"联邦毒品法将把大麻列为滥用风险较低、有公认医疗用途的药物。法案成为法律后，司法部长有60天时间，把大麻从附表一转入附表三。附表一是最严格的类别，针对滥用风险高、且没有公认医疗用途的药物。\n\n大麻在联邦法律下仍然是受管制药物。这次调整将跳过通常的步骤，例如卫生部门的审查和公开听证会。工业大麻（hemp）仍与现在一样，不受这些毒品规定的约束。","updatedAt":"2026-10-25T17:22:34.613839+00:00"}